Biotech specialized in precision medicine, our mission is to bring innovative therapeutic and diagnostic solutions to treat resistant and metastasis cancer.. .
Parfait, votre titre contient entre 10 et 70 caractères.
Génial, votre balise META description contient entre 70 et 160 caractères.
Nous avons trouvé 12 image(s) sur cette page Web. 2 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.
Bien, le ratio de cette page texte/HTML est supérieur à 15, mais inférieur à 25 pour cent.
Parfait, aucun contenu FLASH n'a été détecté sur cette page.
Génial, il n'y a pas d'Iframes détectés sur cette page.
| locale | en_GB |
|---|---|
| locale:alternate | fr_FR |
| type | website |
| title | Oncodesign Precision Medicine |
| description | Biotech specialized in precision medicine, our mission is to bring innovative therapeutic and diagnostic solutions to treat resistant and metastasis cancer. |
| url | http://www.oncodesign.com/ |
| site_name | Oncodesign Precision Medicine |
| image | https://www.oncodesign.com/wp-content/uploads/2022/09/oncodesign-pm-home-intro.png |
| image:width | 599 |
| image:height | 493 |
| image:type | image/png |
Liens internes 95.83%
Liens externes [Passing Juice 4.17%]
Liens externes [noFollow 0%]
| Texte d'ancre | Link | Type | Juice |
|---|---|---|---|
| Learn more | https://oncodesign-services.com/ | Externe | Passing Juice |
| Our pipeline | https://oncodesign.com/our-pipeline/ | Interne | Passing Juice |
| Partnering | https://oncodesign.com/our-pipeline/partnering/ | Interne | Passing Juice |
| Our innovation technologies | https://oncodesign.com/our-innovation-technologies/ | Interne | Passing Juice |
| OncoSNIPER | https://oncodesign.com/our-innovation-technologies/oncosniper/ | Interne | Passing Juice |
| Nanocyclix | https://oncodesign.com/our-innovation-technologies/nanocyclix/ | Interne | Passing Juice |
| PROMETHE | https://oncodesign.com/our-innovation-technologies/theranostics/ | Interne | Passing Juice |
| Investors | https://oncodesign.com/investors/ | Interne | Passing Juice |
| Message from the chairman | https://oncodesign.com/investors/message-from-the-chairman/ | Interne | Passing Juice |
| Regulated information [FR] | https://oncodesign.com/investors/regulated-information/ | Interne | Passing Juice |
| Press Release | https://oncodesign.com/press-release/ | Interne | Passing Juice |
| General Meetings [FR] | https://oncodesign.com/fr/investisseurs/assemblee-generale/ | Interne | Passing Juice |
| About us | https://oncodesign.com/about-us/ | Interne | Passing Juice |
| Latest news | https://oncodesign.com/about-us/news/ | Interne | Passing Juice |
| Our history | https://oncodesign.com/about-us/our-history/ | Interne | Passing Juice |
| Management | https://oncodesign.com/fr/a-propos/management-2/ | Interne | Passing Juice |
| Our HR policy | https://oncodesign.com/about-us/careers/ | Interne | Passing Juice |
| Our CSR approach | https://oncodesign.com/about-us/our-csr-approach/ | Interne | Passing Juice |
| FederAidd | https://oncodesign.com/about-us/federaidd/ | Interne | Passing Juice |
| Contact us | https://oncodesign.com/contact-us/ | Interne | Passing Juice |
| OPM announces a 6 million euros bank financing | https://oncodesign.com/opm-announces-a-6-million-euros-bank-financing/ | Interne | Passing Juice |
| OPM announces positive interim results of its Phase 1 study | https://oncodesign.com/opm-announces-positive-interim-results-of-its-phas | Interne | Passing Juice |
| Legal notice | https://oncodesign.com/legal-notice/ | Interne | Passing Juice |
| Personal data policy | https://oncodesign.com/personal-data-policy/ | Interne | Passing Juice |
| Mot-clef | Contenu | Titre | Mots-clefs | Description | Niveaux de titre |
|---|---|---|---|---|---|
| news | 5 |  |
|
|
 |
| therapeutic | 5 | |
|
|
|
| opm | 4 | |
|
|
|
| learn | 4 | |
|
|
|
| more | 4 | |
|
|
|
| innovative | 3 | |
|
|
|
| pipeline | 3 | |
|
|
|
| read | 3 | |
|
|
|
| innovation | 3 | |
|
|
|
| technologies | 3 | |
|
|
|
| oncodesign | 3 | |
|
|
|
| investors | 3 | |
|
|
|
14 Longueur
Parfait. Votre charset est UTF-8.
Bien. Votre langue est : EN. 
Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.
Génial, votre site web dispose d'un favicon.
Génial, aucune adresse e-mail n'a été trouvé sous forme de texte!
Cette page ne profite pas des métadonnées Dublin Core.
Aucun style CSS pour optimiser l'impression n'a pu être trouvé.
to find the best therapeutic path, our pipeline, our technologies, opm announces a 6 million euros bank financing, opm announces positive interim results of its phase 1 study, attention javascript est désactivé sur votre poste. ce site nécessite l'activation de javascript pour fonctionner correctement., our science, news, oncodesign precision medicine, newsletter, therapeutic, technological, activities, medicine, promethe, newsletter, patients, opportunities, innovative, opm, oncodesign, first--class, nanocyclix, learn, shared, programs, best--class, benefit, goals, all, services, covering, patient, latest, investors, areas, announces, also, october, explore, model, several, oncosniper, discovery, technologies, javascript, science, news, dedicated, highly, innovation, cro, precision, read, solutions, drug, pipeline, attention, more, policy, oncodesign.com.
